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LETTERS TO THE EDITOR
Prehospital Thrombolytic
Therapy for ST-Segment
Elevation Myocardial Infarction
The results of the ER-TIMI (Thrombolysis in Myocardial Infarc-
tion) 19 trial (1) provide yet another building block in the case
for prehospital administration of thrombolytic agents to pa-
tients presenting with acute ST-segment elevation myocardial
infarction (MI). These results reflect as accurately as possible
the contemporary impact on time to administration (32-min
decrease), and they come at a point when there is increasing
focus on the use of percutaneous coronary intervention (PCI) as
an alternative to thrombolysis (2). Despite the modest impact
on timing, I strongly agree with the statement by Morrow et al.
(1) that, with the necessary supportive infrastructure in the
prehospital situation, there is little reason to delay thrombolytic
treatment.
Now that the practical difficulties related to initiating medically
supervised thrombolytic therapy during the prehospital phase have
receded, the question focuses on which patients to treat before
transport. The 12-h time window adopted for this study seems
unsuitable for day-to-day practice. Eligible patients seen within
the first hour or so with conspicuous electrocardiographic
(ECG) evidence of myocardial injury clearly have most to gain
from immediate thrombolytic treatment. For them a saving of
under 30 min may be crucial, and even if short transport and
door-to-drug times are anticipated, administration of a throm-
bolytic agent in the field would seem imperative. In contrast,
those with a symptom duration in excess of 4 h and less
dramatic ECG findings have less to gain and, in places where
medical triage of calls from paramedics could be a limiting
factor, resources might be conserved by waiting until after a
short transit time to the hospital.
Because reperfusion during the early hours after onset is critical
for the salvage of meaningful quantities of myocardium and
because it is inconceivable that timely PCI can be implemented
universally, I believe that facilities for prehospital administration of
thrombolytic therapy should now be made widely available, at least
for patients who seek help quickly. In countries where the
ambulances are staffed by physicians this practice was generally
adopted early in the thrombolytic era. Today it is highly
inappropriate that patients seen early in areas served by para-
medic systems should be deprived of a time-critical treatment,
even for half an hour, because of a difference in medical
organization. If availability of thrombolytic agents in paramedic
vehicles becomes the rule rather than the exception there will be
the opportunity to provide treatment at a time when much more
of the myocardial “horse” is still in the “stable,” resulting in
substantial benefit to patients.
The initial concept of prehospital coronary care envisaged
patients coming under the umbrella of intensive care when the
ambulance arrived: following appropriate stabilization, transport to
the hospital without potentially harmful “haste or fuss” could take
place (3). Widespread adoption of thrombolysis initiated by
supervised paramedics would bring the implementation of this
valid concept fully up to date.
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REPLY
We appreciate Dr. Geddes’ interest and comments on our report of
the results of the ER-TIMI (Thrombolysis in Myocardial Infarc-
tion) 19 trial (1). We concur that it will be important for
emergency medical systems implementing prehospital thrombo-
lytic programs to develop carefully considered eligibility criteria,
including evaluation of the time from symptom onset. However,
the appropriate “time window” for consideration of prehospital
thrombolysis may vary depending on characteristics of each emer-
gency medical system, such as the typical transport times and other
treatment options available. In systems where treatment with a
fibrinolytic is the only option for timely reperfusion therapy and where
field management times are long, we would be reluctant to deprive a
patient presenting within 12 h of symptom onset without contrain-
dications from receiving fibrinolytic as early as possible. The benefit of
fibrinolysis within this time period has been established (2), and there
is little reason to delay therapy once eligibility has been determined.
Certainly, the potential gains from prehospital fibrinolysis are
less in patients presenting later in the course of acute myocardial
infarction (AMI) (3). Thus, we agree that for patients activating
the emergency medical response 6 to 12 h after symptom onset,
other factors may be included in the decision whether to admin-
ister fibrinolytic prehospital. For example, in systems where the
field management times are short (e.g., 20 min), patients with
relative contraindications to fibrinolysis who are also presenting
late may be served best by additional evaluation in the emergency
department. Also, based on recent findings from the DANish
multicenter randomized study on thrombolytic therapy versus acute
coronary angioplasty in Acute Myocardial Infarction (DANAMI)-2
Trial (4), systems in which transfer for primary percutaneous coronary
intervention is possible may wish to consider prehospital thrombolysis
only for patients presenting very early after symptom onset. Such a
strategy of deferring thrombolysis will hinge upon the expected
door-to-balloon times for transferred patients.
Given the wide variation in each of these factors between
emergency medical systems, it seems reasonable to tailor the details
of a prehospital thrombolytic program to the system in which it
will operate. In all cases, the decision whether to administer
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prehospital fibrinolytic should be made by the supervising physi-
cian on the basis of an integrated assessment of the clinical
presentation, electrocardiogram, and treatment options available.
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